Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
48 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-06-20
Study Completion Date
2025-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research project is to investigate the safety and tolerability of an approved drug (Apomorphine) when administered as a nasal powder spray formulation (NT-301) as well as collect information on how NT-301 moves into, through and out of your body, called Pharmacokinetics.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers
NCT03542916
Healthy Subjects
COMPLETED
PHASE1
A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects
NCT04846998
Smoking Cessation
COMPLETED
PHASE1
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450
Cardiovascular Disease
COMPLETED
PHASE1
Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects
NCT01365624
Healthy Subjects
COMPLETED
PHASE1
Sublingual vs IV Atropine Bioavailability Study
NCT04290039
Toxic Effect of Organophosphate and Carbamate Insecticides
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Single Ascending Dose (SAD)- 4 groups will receive a single dose only. Each group receiving a dose higher than the previous cohort. Some participants will get a nasal spray containing NT-301 and others will get a placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Tolerability of NT-301 Nasal Spray
Pharmacokinetics of NT-301 Nasal Spray
Safety of NT-301 Nasal Spray
Performance of NT-301 Nasal Spray Device
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Single ascending dose trial in the first part (4 cohorts)
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Blinded CRO project manager and medical affairs professional
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo 1 mg
Matching Placebo for 1 mg NT-301
Group Type
PLACEBO_COMPARATOR
NT-301 1 mg
Intervention Type
COMBINATION_PRODUCT
unidose of 1 mg apomorphine through nasal spray
Placebo 1 mg
Intervention Type
COMBINATION_PRODUCT
Matching Placebo to NT-301 1 mg
Placebo 2 mg
Matching placebo for NT-301 2 mg strength
Group Type
PLACEBO_COMPARATOR
NT-301 2 mg
Intervention Type
COMBINATION_PRODUCT
unidose of 2 mg apomorphine through nasal spray
Placebo 2 mg
Intervention Type
COMBINATION_PRODUCT
Matching Placebo to NT-301 2 mg
NT-301 1 mg
NT-301 nasal spray 1 mg strength
Group Type
EXPERIMENTAL
NT-301 1 mg
Intervention Type
COMBINATION_PRODUCT
unidose of 1 mg apomorphine through nasal spray
NT-301 2 mg
NT-301 nasal spray 2 mg strength
Group Type
EXPERIMENTAL
NT-301 2 mg
Intervention Type
COMBINATION_PRODUCT
unidose of 2 mg apomorphine through nasal spray
Placebo 3 mg
Matching placebo for NT-301 3 mg
Group Type
PLACEBO_COMPARATOR
Placebo 3 mg
Intervention Type
COMBINATION_PRODUCT
Matching Placebo to NT-301 3 mg
placebo 4 mg
Matching placebo for NT-301 4 mg
Group Type
PLACEBO_COMPARATOR
Placebo 4 mg
Intervention Type
COMBINATION_PRODUCT
Matching placebo to NT-301 4 mg
NT-301 3 mg
Apomorphine nasal spray 3 mg
Group Type
ACTIVE_COMPARATOR
NT-301 3 mg
Intervention Type
COMBINATION_PRODUCT
unidose apomorphine nasal spray 3 mg
NT-301 4 mg
apomorphine nasal spray 4 mg
Group Type
EXPERIMENTAL
NT-301 4 mg
Intervention Type
COMBINATION_PRODUCT
unidose apomorphine nasal spray 4 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NT-301 1 mg
unidose of 1 mg apomorphine through nasal spray
Intervention Type
COMBINATION_PRODUCT
NT-301 2 mg
unidose of 2 mg apomorphine through nasal spray
Intervention Type
COMBINATION_PRODUCT
Placebo 1 mg
Matching Placebo to NT-301 1 mg
Intervention Type
COMBINATION_PRODUCT
Placebo 2 mg
Matching Placebo to NT-301 2 mg
Intervention Type
COMBINATION_PRODUCT
Placebo 3 mg
Matching Placebo to NT-301 3 mg
Intervention Type
COMBINATION_PRODUCT
NT-301 3 mg
unidose apomorphine nasal spray 3 mg
Intervention Type
COMBINATION_PRODUCT
NT-301 4 mg
unidose apomorphine nasal spray 4 mg
Intervention Type
COMBINATION_PRODUCT
Placebo 4 mg
Matching placebo to NT-301 4 mg
Intervention Type
COMBINATION_PRODUCT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female participants aged between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
2. Body weight ≥50 kg and body mass index (BMI) within the range of 18 to 32 kg/m2 inclusive at screening.
3. Woman of childbearing potential (WOCBP) or fertile male participants must agree to use an acceptable method of contraception from the start of Screening until 90 days (male participants) or 60 days (female participants) after the final study visit.
4. WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the first dose of study intervention (including domperidone) and be willing to have additional pregnancy tests, as required, throughout the study.
5. Participants must be in good general health, as demonstrated at screening and prior to first administration of any study intervention (including domperidone) by the absence of clinically significant (in the opinion of the Investigator) abnormalities based on a medical evaluation including review of medical history, physical examination, safety laboratory tests, vital signs, 12-lead ECG monitoring.
Note: It is the responsibility of the Investigator to assess the clinical significance of any abnormality/ies; however, consultation with the MM may be warranted.
6. Normal vital signs after ≥5 min resting in supine position:
1. ≥90 mmHg and ≤160 mmHg systolic blood pressure (SBP)
2. ≥50 mmHg and ≤95 mmHg diastolic blood pressure (DBP)
3. ≥ 45 bpm and ≤100 bpm heart rate (HR)
4. Body temperature (tympanic) ≥35.5°C and ≤37.7°C
7. No clinically significant changes and/or associated symptoms considered related to orthostatic hypotension when measuring blood pressure (BP) and pulse rate (PR) within 2 min of standing from a supine position.
8. Triplicate 12-lead ECG, taken after ≥5 min in a supine, position, with a QT interval corrected using the Fridericia method (QTcF) ≤ 450 msec for males and ≤ 470 msec for females, PR interval ≤ 220 msec or QRS duration ≤ 120 msec or history of long QT syndrome and no clinically significant abnormalities as judged by the Investigator (or qualified designee).
9. Willing and able to be confined at the CRU for the study period and adhere to overall study visit schedule, procedures and other protocol requirements, as assessed by the Investigator (or qualified designee).
10. Understands and voluntarily signs an informed consent document prior to any study related assessments/procedures being conducted.
2. Body weight ≥50 kg and body mass index (BMI) within the range of 18 to 32 kg/m2 inclusive at screening.
3. Woman of childbearing potential (WOCBP) or fertile male participants must agree to use an acceptable method of contraception from the start of Screening until 90 days (male participants) or 60 days (female participants) after the final study visit.
4. WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the first dose of study intervention (including domperidone) and be willing to have additional pregnancy tests, as required, throughout the study.
5. Participants must be in good general health, as demonstrated at screening and prior to first administration of any study intervention (including domperidone) by the absence of clinically significant (in the opinion of the Investigator) abnormalities based on a medical evaluation including review of medical history, physical examination, safety laboratory tests, vital signs, 12-lead ECG monitoring.
Note: It is the responsibility of the Investigator to assess the clinical significance of any abnormality/ies; however, consultation with the MM may be warranted.
6. Normal vital signs after ≥5 min resting in supine position:
1. ≥90 mmHg and ≤160 mmHg systolic blood pressure (SBP)
2. ≥50 mmHg and ≤95 mmHg diastolic blood pressure (DBP)
3. ≥ 45 bpm and ≤100 bpm heart rate (HR)
4. Body temperature (tympanic) ≥35.5°C and ≤37.7°C
7. No clinically significant changes and/or associated symptoms considered related to orthostatic hypotension when measuring blood pressure (BP) and pulse rate (PR) within 2 min of standing from a supine position.
8. Triplicate 12-lead ECG, taken after ≥5 min in a supine, position, with a QT interval corrected using the Fridericia method (QTcF) ≤ 450 msec for males and ≤ 470 msec for females, PR interval ≤ 220 msec or QRS duration ≤ 120 msec or history of long QT syndrome and no clinically significant abnormalities as judged by the Investigator (or qualified designee).
9. Willing and able to be confined at the CRU for the study period and adhere to overall study visit schedule, procedures and other protocol requirements, as assessed by the Investigator (or qualified designee).
10. Understands and voluntarily signs an informed consent document prior to any study related assessments/procedures being conducted.
Exclusion Criteria
1. Any significant medical condition, physical or psychiatric illness or history of depression that could, in the Investigator's (or qualified designee) opinion, compromise the participant's safety or interfere with the completion of this study.
2. History of clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure.
3. Any condition including the presence of laboratory abnormalities, which according to the Investigator (or qualified designee), places the participant at unacceptable risk if they were to participate in the study or may confound the ability to interpret data from the study. This includes the presence of uncontrolled current illness (e.g., an infection), a viral infection, seasonal allergy, or concurrent skin rash.
4. Any nasal condition, including nasal congestion, physical blockage of either nostril, deviated septum, structural or anatomical nasal conditions or nasal surgery in the last 6 months. Use of topical nasal medications (e.g., acute or chronic use of prescription or over the counter nasal sprays) that may affect the administration or absorption of the study drug.
5. Use of 5HT3 antagonists, drugs known to prolong QTc, and use of antihypertensives.
6. The participant has a medical history of or a positive blood test for human immunodeficiency virus (HIV: HIV, anti-HIV1 and anti-HIV2 antibodies), hepatitis C virus (HCV, anti-HCV antibodies), or hepatitis B surface antigen (HBsAg) at screening.
7. Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatine, or total bilirubin \>1.5x the upper limit of normal (ULN). These laboratory tests may be repeated once if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the normal range, the participant may be included in the study only if the Investigator (or qualified designee) considers that the previous finding will not compromise the participant's safety and will not interfere with the interpretation of safety data.
8. A positive drug or alcohol screen. A positive drug or alcohol screen test result may be verified by re-testing at the discretion of the Investigator (or qualified designee), with up to 1 false positive result permitted.
9. History of regular alcohol consumption within 6 months of screening defined as an average weekly intake of \>21 units. One unit is equivalent to 10 g of alcohol and the following can be used as a guide: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (30 mL) measure of spirits.
10. The participant is unwilling to abstain from alcohol consumption from 24 h prior to treatment with any study intervention (including domperidone) and until discharge from the CRU, and for 24 h prior to all other outpatient visits to the CRU.
11. The participant is pregnant or planning to become pregnant within 90 days of the study or is breastfeeding.
12. Major surgery within 4 weeks of screening that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the participant in the opinion of the Investigator (or qualified designee).
13. Use of tobacco or nicotine products exceeding 5 cigarettes (or equivalent) per week in any form within 30 days prior to treatment with any study intervention (including domperidone), or unwillingness to refrain from smoking, vaping, or using any nicotine products for at least 48 h prior to dosing with any study intervention (including domperidone), the confinement period, and any follow up visits.
14. The participant uses or is planning to use any prescription or non-prescription medications (with the exception of hormonal contraceptives), herbal and dietary supplements, within 5 days or 5 half-lives (whichever is longer) prior to treatment with any study intervention (including domperidone), unless in the opinion of the PI, local MM and Sponsor medical representative, the medication is not expected to interfere with the study procedures or compromise participant safety
15. Participation in a clinical trial and receipt of an investigational medication within 90 days, 5 half-lives (if known) or twice the duration of the biological effect of any medication, whichever is longer, prior to the first dose of study intervention.
16. Use of any strong CYP450-3A4/5 inhibiting or inducing agents within 14 days of dosing with any study intervention (including domperidone) and for the duration of the study.
17. Consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice, Seville oranges, within 14 days prior to dosing with any study intervention (including domperidone) and participant is unwilling to abstain from consumption of these products until after discharge from the CRU.
18. Participant is unwilling to abstain from the consumption of caffeine and/or xanthine containing products (e.g., coffee, tea, chocolate, and caffeine containing sodas, etc.) from time of admission to the CRU on Day -1 until after discharge from the CRU.
19. Known sensitivity to any study intervention, including NT-301, apomorphine HCl and domperidone.
20. Loss or donation of whole blood (\>499 mL) within 3 months and/or plasma donation within 2 weeks, prior to dosing with any study intervention (including domperidone), or intention to donate blood or blood products during the study.
21. The participant has a history of cancer, with the exception of basal cell carcinoma or in situ cervical cancer that has been in remission for ≥5 years prior to first dose of study treatment.
22. Participants with a pre-disposition to nausea and vomiting (e.g., history of severe travel sickness).
23. The participant is unwilling or unable to follow protocol requirements, including domperidone self-administration and diary completion, and attendance at follow up visit(s), or otherwise unsuitable for study participation in the opinion of the Investigator.
2. History of clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure.
3. Any condition including the presence of laboratory abnormalities, which according to the Investigator (or qualified designee), places the participant at unacceptable risk if they were to participate in the study or may confound the ability to interpret data from the study. This includes the presence of uncontrolled current illness (e.g., an infection), a viral infection, seasonal allergy, or concurrent skin rash.
4. Any nasal condition, including nasal congestion, physical blockage of either nostril, deviated septum, structural or anatomical nasal conditions or nasal surgery in the last 6 months. Use of topical nasal medications (e.g., acute or chronic use of prescription or over the counter nasal sprays) that may affect the administration or absorption of the study drug.
5. Use of 5HT3 antagonists, drugs known to prolong QTc, and use of antihypertensives.
6. The participant has a medical history of or a positive blood test for human immunodeficiency virus (HIV: HIV, anti-HIV1 and anti-HIV2 antibodies), hepatitis C virus (HCV, anti-HCV antibodies), or hepatitis B surface antigen (HBsAg) at screening.
7. Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatine, or total bilirubin \>1.5x the upper limit of normal (ULN). These laboratory tests may be repeated once if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the normal range, the participant may be included in the study only if the Investigator (or qualified designee) considers that the previous finding will not compromise the participant's safety and will not interfere with the interpretation of safety data.
8. A positive drug or alcohol screen. A positive drug or alcohol screen test result may be verified by re-testing at the discretion of the Investigator (or qualified designee), with up to 1 false positive result permitted.
9. History of regular alcohol consumption within 6 months of screening defined as an average weekly intake of \>21 units. One unit is equivalent to 10 g of alcohol and the following can be used as a guide: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (30 mL) measure of spirits.
10. The participant is unwilling to abstain from alcohol consumption from 24 h prior to treatment with any study intervention (including domperidone) and until discharge from the CRU, and for 24 h prior to all other outpatient visits to the CRU.
11. The participant is pregnant or planning to become pregnant within 90 days of the study or is breastfeeding.
12. Major surgery within 4 weeks of screening that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the participant in the opinion of the Investigator (or qualified designee).
13. Use of tobacco or nicotine products exceeding 5 cigarettes (or equivalent) per week in any form within 30 days prior to treatment with any study intervention (including domperidone), or unwillingness to refrain from smoking, vaping, or using any nicotine products for at least 48 h prior to dosing with any study intervention (including domperidone), the confinement period, and any follow up visits.
14. The participant uses or is planning to use any prescription or non-prescription medications (with the exception of hormonal contraceptives), herbal and dietary supplements, within 5 days or 5 half-lives (whichever is longer) prior to treatment with any study intervention (including domperidone), unless in the opinion of the PI, local MM and Sponsor medical representative, the medication is not expected to interfere with the study procedures or compromise participant safety
15. Participation in a clinical trial and receipt of an investigational medication within 90 days, 5 half-lives (if known) or twice the duration of the biological effect of any medication, whichever is longer, prior to the first dose of study intervention.
16. Use of any strong CYP450-3A4/5 inhibiting or inducing agents within 14 days of dosing with any study intervention (including domperidone) and for the duration of the study.
17. Consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice, Seville oranges, within 14 days prior to dosing with any study intervention (including domperidone) and participant is unwilling to abstain from consumption of these products until after discharge from the CRU.
18. Participant is unwilling to abstain from the consumption of caffeine and/or xanthine containing products (e.g., coffee, tea, chocolate, and caffeine containing sodas, etc.) from time of admission to the CRU on Day -1 until after discharge from the CRU.
19. Known sensitivity to any study intervention, including NT-301, apomorphine HCl and domperidone.
20. Loss or donation of whole blood (\>499 mL) within 3 months and/or plasma donation within 2 weeks, prior to dosing with any study intervention (including domperidone), or intention to donate blood or blood products during the study.
21. The participant has a history of cancer, with the exception of basal cell carcinoma or in situ cervical cancer that has been in remission for ≥5 years prior to first dose of study treatment.
22. Participants with a pre-disposition to nausea and vomiting (e.g., history of severe travel sickness).
23. The participant is unwilling or unable to follow protocol requirements, including domperidone self-administration and diary completion, and attendance at follow up visit(s), or otherwise unsuitable for study participation in the opinion of the Investigator.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMAX Clinical Research Pty Limited
UNKNOWN
Sponsor Role
collaborator
Beyond Drug Development
UNKNOWN
Sponsor Role
collaborator
Nano PharmaSolutions Australia
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CMAX Clinical Research Center Pty Limited
Adelaide, South Australia, Australia
Site Status
RECRUITING
CMAX
Adelaide, South Australia, Australia
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Australia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Acacia Lawrie, B.A
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NT-301-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects
NCT00968422
COMPLETED
PHASE1
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
NCT01199965
COMPLETED
PHASE1/PHASE2
Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers
NCT03565861
COMPLETED
PHASE1
A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects
NCT02020486
COMPLETED
PHASE1
A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects
NCT00854659
COMPLETED
PHASE1
A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers
NCT00614016
COMPLETED
PHASE1
Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
NCT02110459
COMPLETED
PHASE1
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507
RECRUITING
PHASE1
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
NCT05933187
COMPLETED
PHASE1
AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects
NCT00995605
TERMINATED
PHASE1
Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects
NCT01258491
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
NCT06744439
COMPLETED
PHASE1
The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects
NCT04686825
COMPLETED
PHASE1
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04249284
COMPLETED
PHASE1
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
NCT05644600
TERMINATED
PHASE1
Comparative Pharmacokinetic Study of Aprepitant Injection in Humans
NCT06226506
NOT_YET_RECRUITING
PHASE1
Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)
NCT01244035
COMPLETED
PHASE1
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
NCT07282145
RECRUITING
PHASE1
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
NCT07063342
RECRUITING
PHASE1
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04200573
COMPLETED
PHASE1
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
NCT07219030
RECRUITING
PHASE1
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
NCT02436447
COMPLETED
PHASE1
Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
NCT03133130
COMPLETED
PHASE1
Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers
NCT01363050
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
NCT04859426
COMPLETED
PHASE1